VANCOUVER, May 13, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the first quarter ended March 31, 2013.

VANCOUVER, May 2, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced completion of the transfer of sponsorship of the U.S.

Vancouver, Canada, May 9, 2013 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the first quarter ended March 31, 2013 on the afternoon of Monday, May 13, 2013.

VANCOUVER, April 25, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has taken on responsibility for worldwide sales, marketing, and promotion of BRINAVESS� (vernakalant IV) pursuant to a Transition ...

Cardiome Pharma Corp. has completed the transfer of sponsorship of the US Investigational New Drug Applications for vernakalant intravenous (IV) and oral, and the transfer of the US New Drug Application for vernakalant IV from Merck Sharp & Dohme ...

... CORP Q1 UNDESIGNATED CONR SVC USD -0.01 0.00 0.01 4.5 4.4 -0.1 CAPSTONE INFRASTRUCTURE Q1 ELECTRICAL UTILITIES CAD 0.13 -- -- 95.4 94.3 -1.1 CARDIOME PHARMA CORP Q1 DRUGS USD -- -- -- -- 0.1 -- CARDIOME PHARMA CORP ...

Cardiome Pharma Corp. (NASDAQ: CRME) is projected to report its Q1 earnings on revenue of $1.60 million. Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) is estimated to report its Q1 earnings at $0.28 per share on revenue of $12.81 million.

Dr. Bednarik was formerly Director of Genomics and Bioinformatics for Cardiome Pharma Corporation. He was previously co-founder and Vice President of Cardiovascular Biology of Artesian Therapeutics, Inc., which was acquired by Cardiome in 2005.